to extend your reach and impact.
We work with leading private equity and venture capital investors globally, leveraging our deep life sciences & healthcare experience, knowledge and industry connections to commercially assess potential investment opportunities. Our due diligences are thorough, highly analytical and rooted in ensuring the most robust and impactful investments are selected.
Coverage can include:
As new technological paradigms mature and value propositions shift to drive long-term healthcare value and impact, it is critical that private equity and venture capital stays at the forefront of industry shifts and changes. We help clients to become and stay deeply immersed in the current state of the industry and where it is heading, allowing them to be ahead of the curve when identifying and assessing targets.
Coverage can include:
Generating the highest value from investments in life sciences and healthcare involves identifying and developing scalable solutions that enhance the therapeutic area top line across the drug value chain or improve the efficiency & quality of patient services. We help private equity and venture capital investors transform current investments into leading pharma, medtech, biotech, healthcare, digital health companies.
Strategic services offered include:
Our deep life sciences & healthcare experience, knowledge and industry connections allows private equity and venture capital investors to stay ahead of the curve and proactively identify potential targets before a formal deal process is initiated.
The ability to embed external thinking, experience, and urgency in execution into your portfolio in an agile and dynamic manner is key to scalable & sustainable growth. At Reformulate, we can provide you with experienced entrepreneurs and industry executives who are ‘entrepreneurs in residence’ across your portfolio. Our ‘entrepreneur in residence’ will form a key part of your team for a period as short or as long as needed, with the goal of mentoring and coaching your portfolio founders and executives, to accelerate time-to-value for your investments.
In this JMIR publication Dr Ramin Rafiei and Dr Timothy Aungst measure the digital health maturity of the top 15 biopharmaceutical companies in the US biologics market and establish the framework for next-generation autoinjectable devices powering home-based precision care.